FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2034204078> ?p ?o ?g. }

• W2034204078 abstract "Treprostinil diethanolamine is an innovative salt form of the prostacyclin analogue, treprostinil sodium, developed as an oral sustained release (SR) osmotic tablet. The availability of a formulation permitting convenient systemic delivery might have applicability to scleroderma vascular complications. We evaluated pharmacokinetics and perfusion in scleroderma patients with digital ischemia following escalating twice-daily doses of treprostinil diethanolamine SR.Scleroderma patients with digital ulcers were enrolled in this dual-center, open-label, phase I pharmacokinetic study. Drug concentrations and perfusion, quantified by laser Doppler imaging, were measured over 12 hours at the 2 mg and 4 mg (or maximally tolerated) doses. Pharmacokinetic parameters were determined from individual plasma concentration versus time profiles using non-compartmental analysis methods. Digital perfusion and skin temperature were modeled as a function of log-transformed drug concentration and other covariates by performing repeated measures analyses using random effects models.Nineteen scleroderma patients (84% female, 53% limited scleroderma) received treprostinil diethanolamine SR with dose titration up to 4 mg twice daily as tolerated. Peak concentrations (mean maximum plasma concentration (Cmax) = 1,176 and 2,107 pg/mL) occurred approximately 3.6 hours after dose administration, and overall exposure (under the plasma concentration-time curve from time 0 to 12 hours post dose (AUC0-12) = 7,187 and 12,992 hr*pg/mL) was linear between the 2 mg and 4 mg doses. Perfusion and digital skin temperature were positively associated with log-transformed plasma concentration at the 4 mg dose (P = 0.015 and P = 0.013, respectively). The most frequent adverse events were similar to those seen with prostacyclin analogues.Oral treprostinil diethanolamine was effectively absorbed in patients with scleroderma. Drug administration was temporally associated with improved cutaneous perfusion and temperature. Treprostinil diethanolamine may provide a new therapeutic option for Raynaud's phenomenon and the peripheral vascular disease of scleroderma.ClinicalTrials.gov NCT00848939." @default.
• W2034204078 created "2016-06-24" @default.
• W2034204078 creator A5000524323 @default.
• W2034204078 creator A5000610272 @default.
• W2034204078 creator A5006126520 @default.
• W2034204078 creator A5008093033 @default.
• W2034204078 creator A5009211703 @default.
• W2034204078 creator A5014755352 @default.
• W2034204078 creator A5019236240 @default.
• W2034204078 creator A5040282565 @default.
• W2034204078 creator A5068528030 @default.
• W2034204078 creator A5068981399 @default.
• W2034204078 creator A5084784795 @default.
• W2034204078 date "2013-04-01" @default.
• W2034204078 modified "2023-10-06" @default.
• W2034204078 title "Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion" @default.
• W2034204078 cites W1808650160 @default.
• W2034204078 cites W1970780902 @default.
• W2034204078 cites W1977777133 @default.
• W2034204078 cites W1997313140 @default.
• W2034204078 cites W1998291301 @default.
• W2034204078 cites W2006708492 @default.
• W2034204078 cites W2015086761 @default.
• W2034204078 cites W2028921539 @default.
• W2034204078 cites W2034836771 @default.
• W2034204078 cites W2035384054 @default.
• W2034204078 cites W2055295362 @default.
• W2034204078 cites W2070986045 @default.
• W2034204078 cites W2078934278 @default.
• W2034204078 cites W2086737296 @default.
• W2034204078 cites W2088238100 @default.
• W2034204078 cites W2099636275 @default.
• W2034204078 cites W2114017226 @default.
• W2034204078 cites W2118134979 @default.
• W2034204078 cites W2118846800 @default.
• W2034204078 cites W2130371595 @default.
• W2034204078 cites W2133661117 @default.
• W2034204078 cites W2156654932 @default.
• W2034204078 cites W2170514012 @default.
• W2034204078 cites W2312794029 @default.
• W2034204078 cites W2144622283 @default.
• W2034204078 doi "https://doi.org/10.1186/ar4216" @default.
• W2034204078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5011881" @default.
• W2034204078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23597147" @default.
• W2034204078 hasPublicationYear "2013" @default.
• W2034204078 type Work @default.
• W2034204078 sameAs 2034204078 @default.
• W2034204078 citedByCount "25" @default.
• W2034204078 countsByYear W20342040782013 @default.
• W2034204078 countsByYear W20342040782014 @default.
• W2034204078 countsByYear W20342040782015 @default.
• W2034204078 countsByYear W20342040782016 @default.
• W2034204078 countsByYear W20342040782017 @default.
• W2034204078 countsByYear W20342040782018 @default.
• W2034204078 countsByYear W20342040782019 @default.
• W2034204078 countsByYear W20342040782020 @default.
• W2034204078 countsByYear W20342040782021 @default.
• W2034204078 countsByYear W20342040782023 @default.
• W2034204078 crossrefType "journal-article" @default.
• W2034204078 hasAuthorship W2034204078A5000524323 @default.
• W2034204078 hasAuthorship W2034204078A5000610272 @default.
• W2034204078 hasAuthorship W2034204078A5006126520 @default.
• W2034204078 hasAuthorship W2034204078A5008093033 @default.
• W2034204078 hasAuthorship W2034204078A5009211703 @default.
• W2034204078 hasAuthorship W2034204078A5014755352 @default.
• W2034204078 hasAuthorship W2034204078A5019236240 @default.
• W2034204078 hasAuthorship W2034204078A5040282565 @default.
• W2034204078 hasAuthorship W2034204078A5068528030 @default.
• W2034204078 hasAuthorship W2034204078A5068981399 @default.
• W2034204078 hasAuthorship W2034204078A5084784795 @default.
• W2034204078 hasBestOaLocation W20342040781 @default.
• W2034204078 hasConcept C112705442 @default.
• W2034204078 hasConcept C126322002 @default.
• W2034204078 hasConcept C146957229 @default.
• W2034204078 hasConcept C22979827 @default.
• W2034204078 hasConcept C2776432619 @default.
• W2034204078 hasConcept C2780930700 @default.
• W2034204078 hasConcept C42219234 @default.
• W2034204078 hasConcept C71924100 @default.
• W2034204078 hasConcept C98274493 @default.
• W2034204078 hasConceptScore W2034204078C112705442 @default.
• W2034204078 hasConceptScore W2034204078C126322002 @default.
• W2034204078 hasConceptScore W2034204078C146957229 @default.
• W2034204078 hasConceptScore W2034204078C22979827 @default.
• W2034204078 hasConceptScore W2034204078C2776432619 @default.
• W2034204078 hasConceptScore W2034204078C2780930700 @default.
• W2034204078 hasConceptScore W2034204078C42219234 @default.
• W2034204078 hasConceptScore W2034204078C71924100 @default.
• W2034204078 hasConceptScore W2034204078C98274493 @default.
• W2034204078 hasIssue "2" @default.
• W2034204078 hasLocation W20342040781 @default.
• W2034204078 hasLocation W20342040782 @default.
• W2034204078 hasLocation W20342040783 @default.
• W2034204078 hasLocation W20342040784 @default.
• W2034204078 hasLocation W20342040785 @default.
• W2034204078 hasOpenAccess W2034204078 @default.
• W2034204078 hasPrimaryLocation W20342040781 @default.
• W2034204078 hasRelatedWork W1532498158 @default.
• W2034204078 hasRelatedWork W1969574919 @default.
• W2034204078 hasRelatedWork W2370929226 @default.

• next